Ultragenyx Pharmaceutical Quote - 0LIF

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

64.79

Bid

0.00

Offer

0.00

Volume

408

0.00 Day's Range 0.00

64.79 52 Week Range 64.79

Market Cap

3.27B

Previous Close

64.79

Open

Last Trade

200

40.4

(O)

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

265

Shares Outstanding

82,114,000

Dividend Yield

PE Ratio

-5.39

Earnings Per Share (EPS)

-7.39

Revenue

434.25M

Net Profit

-606.64M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.ultragenyx.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Ultragenyx Pharmaceutical Inc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 0LIF. The last closing price for Ultragenyx Pharmaceutical was US$64.79. Over the last year, Ultragenyx Pharmaceutical shares have traded in a share price range of US$ 64.79 to US$ 64.79.

Ultragenyx Pharmaceutical currently has 82,114,000 shares in issue. The market capitalisation of Ultragenyx Pharmaceutical is US$3.27 billion. Ultragenyx Pharmaceutical has a price to earnings ratio (PE ratio) of -5.39.

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia...

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) For the...

Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH)

Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH) Evkeeza è un farmaco, primo nel...

Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein

Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein Evkeeza® ist das erste von der U.S. Food and Drug...

Period †	Open	High	Low	Avg. Daily Vol	VWAP
1	64.79	64.79	64.79	296	64.79	DE
4	64.79	64.79	64.79	317	64.79	DE
12	64.79	64.79	64.79	265	64.79	DE
26	64.79	64.79	64.79	278	64.79	DE
52	64.79	64.79	64.79	310	64.79	DE
156	64.79	64.79	64.79	1405	64.79	DE
260	64.79	64.79	64.79	1208	64.79	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WELWinchester Energy Ltd	AUD 0.005 (150.00%)	3.28M
CLZClassic Minerals Limited	AUD 0.0015 (50.00%)	3.83M
SITSite Group International Ltd	AUD 0.003 (50.00%)	750k
RADORadiopharm Theranostics Ltd	AUD 0.01 (42.86%)	1.19M
MTHOMithril Resources	AUD 0.05 (38.89%)	50k
LDROLode Resources Ltd	AUD 0.001 (-80.00%)	232.38k
BASOBass Oil Limited	AUD 0.001 (-50.00%)	2.63M
BITOCBiotron Ltd	AUD 0.009 (-35.71%)	1.03M
YPBYPB Group Ltd	AUD 0.002 (-33.33%)	2.59M
IBGOIronbark Zinc Limited	AUD 0.002 (-33.33%)	833.33k
88E88 Energy Limited	AUD 0.002 (0.00%)	100.84M
SYASayona Mining Limited	AUD 0.034 (-1.45%)	23.96M
LTRLiontown Resources Limited	AUD 0.85 (-5.82%)	21.32M
IXRIonic Rare Earths Limited	AUD 0.01 (5.26%)	20.62M
IBGIronbark Zinc Limited	AUD 0.003 (-25.00%)	16.71M